Literature DB >> 18640497

Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.

Elizabeth W Newcomb1, Yevgeniy Lukyanov, Michelle Alonso-Basanta, Mine Esencay, Iva Smirnova, Tona Schnee, Yongzhao Shao, Mary Louise Devitt, David Zagzag, William McBride, Silvia C Formenti.   

Abstract

PURPOSE: To assess the effects of noscapine, a tubulin-binding drug, in combination with radiation in a murine glioma model. METHODS AND MATERIALS: The human T98G and murine GL261 glioma cell lines treated with noscapine, radiation, or both were assayed for clonogenic survival. Mice with established GL261 hind limb tumors were treated with noscapine, radiation, or both to evaluate the effect of noscapine on radioresponse. In a separate experiment with the same treatment groups, 7 days after radiation, tumors were resected and immunostained to measure proliferation rate, apoptosis, and angiogenic activity.
RESULTS: Noscapine reduced clonogenic survival without enhancement of radiosensitivity in vitro. Noscapine combined with radiation significantly increased tumor growth delay: 5, 8, 13, and 18 days for control, noscapine alone, radiation alone, and the combination treatment, respectively (p < 0.001). To assess the effect of the combination of noscapine plus radiation on the tumor vasculature, tubule formation by the murine endothelial 2H11 cells was tested. Noscapine with radiation significantly inhibited tubule formation compared with radiation alone. By immunohistochemistry, tumors treated with the combination of noscapine plus radiation showed a decrease in BrdU incorporation, an increase in apoptosis by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling, and a decrease in tumor vessel density compared with tumors treated with radiation alone.
CONCLUSION: Noscapine enhanced the sensitivity of GL261 glioma tumors to radiation, resulting in a significant tumor growth delay. An antiangiogenic mechanism contributed to the effect. These findings are clinically relevant, particularly in view of the mild toxicity profile of this drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640497      PMCID: PMC2572218          DOI: 10.1016/j.ijrobp.2008.04.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  44 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.

Authors:  R M Salloum; N T Jaskowiak; H J Mauceri; S Seetharam; M A Beckett; A M Koons; D M Hari; V K Gupta; C Reimer; R Kalluri; M C Posner; S Hellman; D W Kufe; R R Weichselbaum
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.

Authors:  E L Lund; L Bastholm; P E Kristjansen
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

Review 4.  Angiogenesis in gliomas: biology and molecular pathophysiology.

Authors:  Ingeborg Fischer; Jean-Pierre Gagner; Meng Law; Elizabeth W Newcomb; David Zagzag
Journal:  Brain Pathol       Date:  2005-10       Impact factor: 6.508

Review 5.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

Authors:  Phyllis Wachsberger; Randy Burd; Adam P Dicker
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

6.  Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy.

Authors:  Adam P Dicker; Torian L Williams; George Iliakis; Derrick S Grant
Journal:  Am J Clin Oncol       Date:  2003-06       Impact factor: 2.339

7.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

Authors:  C G Lee; M Heijn; E di Tomaso; G Griffon-Etienne; M Ancukiewicz; C Koike; K R Park; N Ferrara; R K Jain; H D Suit; Y Boucher
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

8.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.

Authors:  L Geng; E Donnelly; G McMahon; P C Lin; E Sierra-Rivera; H Oshinka; D E Hallahan
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

9.  Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

Authors:  Derrick S Grant; Torian L Williams; Michael Zahaczewsky; Adam P Dicker
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

10.  Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.

Authors:  C Hess; V Vuong; I Hegyi; O Riesterer; J Wood; D Fabbro; C Glanzmann; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

View more
  9 in total

Review 1.  The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications.

Authors:  Padmashree C G Rida; Dillon LiVecche; Angela Ogden; Jun Zhou; Ritu Aneja
Journal:  Med Res Rev       Date:  2015-07-14       Impact factor: 12.944

2.  Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.

Authors:  Ravi Doddapaneni; Ketan Patel; Nusrat Chowdhury; Mandip Singh
Journal:  Exp Cell Res       Date:  2016-05-10       Impact factor: 3.905

3.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Authors:  Wim Maes; Georgina Galicia Rosas; Bert Verbinnen; Louis Boon; Steven De Vleeschouwer; Jan L Ceuppens; Stefaan W Van Gool
Journal:  Neuro Oncol       Date:  2009-03-31       Impact factor: 12.300

Review 4.  Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?

Authors:  Sergey V Kozin; Dan G Duda; Lance L Munn; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2012-05-09       Impact factor: 13.506

5.  Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.

Authors:  Mahavir B Chougule; Apurva R Patel; Tanise Jackson; Mandip Singh
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

6.  Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.

Authors:  Mahavir B Chougule; Apurva Patel; Pratik Sachdeva; Tanise Jackson; Mandip Singh
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

Review 7.  Antiangiogenic Effect of Alkaloids.

Authors:  Masoud Alasvand; Vahideh Assadollahi; Roberto Ambra; Ehsan Hedayati; Wesam Kooti; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2019-04-21       Impact factor: 6.543

Review 8.  Biology of Glioblastoma Multiforme-Exploration of Mitotic Catastrophe as a Potential Treatment Modality.

Authors:  Barbora Vitovcova; Veronika Skarkova; Kamil Rudolf; Emil Rudolf
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

9.  Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.

Authors:  Ravi Doddapaneni; Ketan Patel; Nusrat Chowdhury; Mandip Singh
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.